HyperMed Imaging, Inc.

HyperMed is developing hyperspectral imaging for medical applications. The technology, originally developed for military surveillance, provides an advanced form of spectroscopy that provides a two-dimensional tissue oxygenation map. The company’s first product, OxyVu, was developed for the US research market and subsequently received FDA 510(k) approval for medical diagnostic applications where the measurement of microvasculature perfusion can assist physicians with patient care. Multiple published studies have demonstrated the clinical utility of OxyVu for the diagnostic assessment of wound healing, diabetic foot ulcers, and amputation planning. The market opportunity for the clinical diagnostic applications for hyperspectral imaging represent a multi-billion market.

HyperMed Imaging, Inc. headquartered in United States, North America, operates in the Health Care, Medical, Medical Device sector. The company focuses on Health Care and has secured $361.6M in funding across 36 round(s). With a team of 1-10 employees, HyperMed Imaging, Inc. is actively contributing to advancements in Health Care. Their latest funding round, Series A - HyperMed Imaging, Inc., raised $5.0M. Discover more about their projects, partnerships, and impact on our platform.